- Conditions
- Developmental Disabilities, Weight Loss, Body Weight, Down Syndrome, Body Weight Changes, Intellectual Disability
- Interventions
- Enhanced Stop Light Diet (eSLD), Conventional Diet (CD), Face-to-face (FTF), Technology (TECH), iPad with FaceTime
- Dietary Supplement · Behavioral · Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 13 Years to 21 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Lawrence, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Aging
- Interventions
- Resistance Exercise Training, Mental Imagery
- Other
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Athens, Ohio
- Conditions
- Autism, Sleep Disturbances in Children, Sleep
- Interventions
- Power Down bedtime manipulation
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 6 Years to 10 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Anxiety, Hypertension
- Interventions
- Clonidine Pill, Hydrochlorothiazide
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Interventions
- ViraSafe: Treatment pushes, BRITE
- Behavioral
- Lead sponsor
- Ksana Health
- Industry
- Eligibility
- 13 Years to 24 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Eugene, Oregon • Pittsburgh, Pennsylvania
- Conditions
- Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
- Interventions
- Radiation, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell, Melphalan
- Radiation · Drug · Biological + 1 more
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hereditary Inclusion Body Myopathy (HIBM)
- Interventions
- Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Costa Mesa, California • New York, New York
- Conditions
- Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Anne Fung MD
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Binge Drinking, HIV
- Interventions
- Placebo, Naltrexone, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers:, Behavioral survey measurements:, Dried Blood Spot (DSB) Testing for Phosphatidylethanol, Ecological Momentary Assessment
- Drug · Behavioral · Diagnostic Test
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections
- Interventions
- Aldesleukin, HAART
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Sleep, Mood
- Interventions
- Dynamic Lighting, Placebo Lighting
- Other
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Tempe, Arizona
- Conditions
- Life Experiences
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Oklahoma State University
- Other
- Eligibility
- 18 Years to 29 Years · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Stillwater, Oklahoma
- Conditions
- Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy, Hemiplegia, Hemiparesis, Multiple Sclerosis, Parkinson Disease, Trauma, Brain, Transverse Myelitis, Friedreich Ataxia
- Interventions
- Seated exercise
- Behavioral
- Lead sponsor
- Burke Medical Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Tumor, Solid
- Interventions
- BDB001 (EIK1001), Atezolizumab
- Drug
- Lead sponsor
- Eikon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sarasota, Florida • Nashville, Tennessee + 1 more
- Conditions
- Focus is on Healthy Subjects
- Interventions
- Reusable, Transparent, and Reconfigurable N95-Equivalent Respirator Masks: Design, Fabrication, and Clinical Trials for Enhanced Adoption
- Device
- Lead sponsor
- SEEUS95 Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pain, Substance Use, Opioid Misuse, Quality of Life
- Interventions
- M2VA Pain Care Pathway (M2VAPCP), Implementation Facilitation
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Essential Tremor
- Interventions
- Placebo, GyroGlove
- Device
- Lead sponsor
- GyroGear Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 3
- States / cities
- Farmington Hills, Michigan • Houston, Texas • Burlington, Vermont
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors, Childhood Soft Tissue Sarcoma, Childhood Bone Sarcoma, Childhood Malignant Intestinal Neoplasm, Childhood Malignant Liver Neoplasm, Childhood Malignant Lung Neoplasm, Childhood Malignant Ovarian Neoplasm, Childhood Malignant Pleural Neoplasm, Childhood Neuroblastic Tumor, Childhood Sarcoma
- Interventions
- Wearing Smartwatch, Patient Report Outcomes, Blood Draw, Clinical Data Review
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Violence in Adolescence
- Interventions
- Multi-level Violence Prevention Intervention - Boys, Multi-level Violence Prevention Intervention - Caregivers
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 11 Years to 14 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Severe Alopecia Areata
- Interventions
- Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 31
- States / cities
- Irvine, California • Santa Ana, California • Aurora, Colorado + 22 more
- Conditions
- Improved VO2max and Cardiac Output in Response to Training
- Interventions
- High intensity interval training
- Other
- Lead sponsor
- California State University, San Marcos
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- San Marcos, California
- Conditions
- Psychotic Disorders
- Interventions
- Mobile After-Care Support (MACS) app
- Behavioral
- Lead sponsor
- Butler Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, Cetuximab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 4
- States / cities
- La Jolla, California • Los Angeles, California • Ann Arbor, Michigan + 1 more